How to generate reliable and predictive CoMFA models

Current Medicinal Chemistry

Volumn 18, Issue 6, 2011, Pages 923-930

  Zhang, Lei ^a   Tsai, Keng Chang ^b   Du, Lupei ^a   Fang, Hao ^a   Li, Minyong ^a   Xu, Wenfang ^a  

^a SHANDONG UNIVERSITY   (China)

^b GENOMICS RESEARCH CENTER   (Taiwan)

Author keywords

Alignment; CoMFA; Conformation; Fields; Grid spacing

Indexed keywords

ACETYLCHOLINESTERASE; BUTENOLIDE; GLYCOGEN SYNTHASE KINASE 3; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR; STRESS ACTIVATED PROTEIN KINASE 1; VASCULOTROPIN RECEPTOR 2;

ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; CONFORMATIONAL TRANSITION; DRUG DESIGN; DRUG RESEARCH; HUMAN; HYDROPHOBICITY; MOLECULAR DYNAMICS; PREDICTION; PRINCIPAL COMPONENT ANALYSIS; PROCESS OPTIMIZATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RELIABILITY;

DATA INTERPRETATION, STATISTICAL; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; REPRODUCIBILITY OF RESULTS;

EID: 79952803470     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711794927702     Document Type: Article

References (99)

1. Lill, M.A. Multi-dimensional QSAR in drug discovery. Drug Discov. Today, 2007, 12, 1013-1017. (Pubitemid 350180557)
2. Yang, G.F.; Huang, X. Development of quantitative structure-activity relationships and its application in rational drug design. Curr. Pharm. Des., 2006, 12, 4601-4611. (Pubitemid 44835148)
3. Cramer, R.D.; Patterson, D.E.; Bunce, J.D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steriods to carrier proteins. J. Am. Chem. Soc., 1988, 110, 5959-5967.
4. Kubinyi, H. QSAR and 3D QSAR in drug design Part 1: Methodology. Drug Discov. Today, 1997, 2, 457-467. (Pubitemid 27450428)
5. Kubinyi, H. QSAR and 3D QSAR in drug design Part 2: Applications and problems. Drug Discov. Today, 1997, 2, 538-546. (Pubitemid 27512944)
6. Podlogar, B.L.; Ferguson, D.M. QSAR and CoMFA: A perspective on the practical application to drug discovery. Drug Des. Discov., 2000, 17, 4-12. (Pubitemid 30410011)
7. Mittal, R.R.; McKinnon, R.A.; Sorich, M.J. Effect of steric molecular field settings on CoMFA predictivity. J. Mol. Model., 2008, 14, 59-67. (Pubitemid 50005299)
8. Bursi, R.; Grootenhuis, P.D.J. Comparative molecular field analysis and energy interaction studies of thrombin-inhibitor complexes. J. Comput. Aided Mol. Des., 1999, 13, 221-232. (Pubitemid 29145096)
9. Dinan, L.; Hormann, R.E.; Fujimoto, T. An extensive ecdysteroid CoMFA. J. Comput. Aided Mol. Des., 1999, 13, 185-207. (Pubitemid 29113107)
10. Melville, J.L.; Hirst, J.D. On the stability of CoMFA models. J. Chem. Inf. Comput. Sci., 2004, 44, 1294-1300.
11. Peterson, S.D.; Schaal, W.; Karlen, A. Improved CoMFA modeling by optimization of settings. J. Chem. Inf. Model., 2006, 46, 355-364. (Pubitemid 43285404)
12. Richard D. Cramer, I., David E. Patterson, and Jeffrey D. Bunce. Comparative Molecular Field Analysis (CoMFA). 1. Effect of Shape on Binding of Steroids to Carrier Proteins. J. Am. Chem. Soc., 1988, 110, 5959-5967.
13. Kubinyi, H. QSAR and 3D QSAR in drug design Part 1: Methodology. Drug Discov. Today, 1997, 2, 457-467. (Pubitemid 27450428)
14. Chavatte, P.; Yous, S.; Beaurain, N.; Mesangeau, C.; Ferry, G.; Lesieur, D. Three-dimensional quantitative structure-activity relationship of arylalkylamine N-acetyltransferase (AANAT) inhibitors: A comparative molecular field analysis. Quant. Struct-Act. Rel., 2002, 20, 414-421.
15. Tsai, K.C.; Lin, T.H. A ligand-based molecular modeling study on some matrix metalloproteinase-1 inhibitors using several 3D QSAR techniques. J. Chem. Inf. Comput. Sci., 2004, 44, 1857-1871.
16. Yu, Z.H.; Niu, C.W.; Ban, S.R.; Wen, X.; Xi, Z. Study on structure-activity relationship of mutation-dependent herbicide resistance acetohydroxyacid synthase through 3D-QSAR and mutation. Chinese Sci. Bull., 2007, 52, 1929-1941. (Pubitemid 47116982)
17. Lei, B.L.; Du, J.; Li, S.Y.; Liu, H.X.; Ren, Y.Y.; Yao, X.J. Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of thiazolone derivatives as hepatitis C virus NS5B polymerase allosteric inhibitors. J. Comput. Aided Mol. Des., 2008, 22, 711-725.
18. Kaur, K.; Talele, T. Structure-based CoMFA and CoMSIA study of indolinone inhibitors of PDK1. J. Comput. Aided Mol. Des., 2009, 23, 25-36.
19. Bernard, P.P.; Kireev, D.B.; Pintore, M.; Chretien, J.R.; Fortier, P.L.; Froment, D. A CoMFA study of enantiomeric organophosphorus inhibitors of acetylcholinesterase. J. Mol. Model., 2000, 6, 618-629.
20. Dessalew, N.; Patel, D.S.; Bharatam, P.V. 3D-QSAR and molecular docking studies on pyrazolopyrimidine derivatives as glycogen synthase kinase-3 beta inhibitors. J. Mol. Graph. Model., 2007, 25, 885-895. (Pubitemid 46216123)
21. Yi, P.; Qiu, M.H. 3D-QSAR and docking studies of aminopyridine carboxamide inhibitors of c-Jun N-terminal kinase-1. Eur. J. Med. Chem., 2008, 43, 604-613. (Pubitemid 351323991)
22. Du, J.; Lei, B.L.; Qin, J.; Liu, H.X.; Yao, X.J. Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking. J. Mol. Graph. Model., 2009, 27, 642-654.
23. Huang, M.L.; Yang, D.Y.; Shang, Z.C.; Zou, J.W.; Yu, Q.S. 3D-QSAR studies on 4-hydroxyphenylpyruvate dioxygenase inhibitors by comparative molecular field analysis (CoMFA). Bioorg. Med. Chem. Lett., 2002, 12, 2271-2275.
24. Aher, Y.D.; Agrawal, A.; Bharatam, P.V.; Garg, P. 3D-QSAR studies of substituted 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas as CCR5 receptor antagonists. J. Mol. Model., 2007, 13, 519-529. (Pubitemid 46404035)
25. Cho, W.J.; Kim, E.K.; Park, I.Y.; Jeong, E.Y.; Kim, T.S.; Le, T.N.; Kim, D.D.; Leed, E.S. Molecular Modeling of 3-arylisoquinoline antitumor agents active against A-549. A comparative molecular field analysis study. Bioorg. Med. Chem., 2002, 10, 2953-2961. (Pubitemid 34761874)
26. Juan, A.A.S. Towards predictive inhibitor design for the EGFR autophosphorylation activity. Eur. J. Med. Chem., 2008, 43, 781-791.
27. Chakraborti, A.K.; Gopalakrishnan, B.; Sobhia, M.E.; Malde, A. 3D-QSAR studies of indole derivatives as phosphodiesterase IV inhibitors. Eur. J. Med. Chem., 2003, 38, 975-982. (Pubitemid 37452424)
28. Ganguly, S.; Banerjee, S. 3D-QSAR studies of imidazole derivatives as Candida albicans P450-demethylase inhibitors. Asian J. Chem., 2008, 20, 4595-4608.
29. Adane, L.; Bharatam, P.V. 3D-QSAR analysis of cycloguanil derivatives as inhibitors of A16V+S108T mutant Plasmodium falciparum dihydrofolate reductase enzyme. J. Mol. Graph. Model., 2009, 28, 357-367.
30. Sufrin, J.R.; Dunn, D.A.; Marshall, G.R. Steric mapping of the L-methionine binding site of ATP:L-methionine S-adenosyltransferase. Mol. Pharmacol., 1981, 19, 307-313. (Pubitemid 11004236)
31. J-P Bjorkroth, T.A.P., and J. Lindroos. Comparative Molecular Field Analysis of Some Clodronic Acid Esters. J. Med. Chem.,1991, 34, 2338-2343.
32. Deborah A. Loughney, C.F.S. A comparison of progestin and androgen receptor binding using the CoMFA technique. J. Comput. Aided Mol. Des.,1992, 6, 569-581.
33. Demeter, D.A.; Weintraub, H.J.R.; Knittel, J.J. The local minima method (LMM) of pharmacophore determination: A protocol for predicting the bioactive conformation of small, conformationally flexible molecules. J. Chem. Inf. Comput. Sci., 1998, 38, 1125-1136. (Pubitemid 128591277)
34. Kroemer, R.T.; Hecht, P.; Guessregen, S.; Liedl, K.R. Improving the predictive quality of CoMFA models. Perspect. Drug Discov. Des., 1998, 12, 41-56. (Pubitemid 128488922)
35. Pei, J.F.; Zhou, J.J.; Xie, G.R.; Chen, H.M.; He, X.F. PARM: A practical utility for drug design. J. Mol. Graph. Model., 2001, 19, 448-454.
36. Peng, T.; Pei, J.F.; Zhou, J.J. 3D-QSAR and receptor modeling of tyrosine kinase inhibitors with flexible atom receptor model (FLARM). J. Chem. Inf. Comput. Sci., 2003, 43, 298-303.
37. Pei, J.F.; Chen, H.; Liu, Z.M.; Han, X.F.; Wang, Q.; Shen, B.; Zhou, J.J.; Lai, L.H. Improving the quality of 3D-QSAR by using flexible-ligand receptor models. J. Chem. Inf. Model., 2005, 45, 1920-1933. (Pubitemid 41784765)
38. Lu, A.J.; Zhou, J.J. Pseudoreceptor models and 3D-QSAR for imidazobenzodiazepines at GABA(A)/BzR subtypes alpha(x)beta(3)gamma(2) [x=1-3, 5, and 6] via flexible atom receptor model. J. Chem. Inf. Comput. Sci., 2004, 44, 1130-1136.
39. Shen, B.; Lu, Z.H.; Chi, X.B.; Lu, H.F.; Ren, T.R. Research on pseudoreceptor models for the inhibitors at GABA receptors via flexible atom receptor model. Acta. Phys-Chimi. Sin., 2005, 21, 800-803. (Pubitemid 41021232)
40. Wichapong, K.; Lindner, M.; Pianwanit, S.; Kokpol, S.; Sippl, W. Receptorbased 3D-QSAR studies of checkpoint Wee1 kinase inhibitors. Eur. J. Med. Chem., 2009, 44, 1383-1395.
41. A. J. Hopfinger, S.W., John S. Tokarski, Baiqiang Jin, Magaly Albuquerque, Prakash J. Madhav, Chaya Duraiswami. Construction of 3D-QSAR Models Using the 4D-QSAR Analysis Formalism. J. Am. Chem. Soc., 1997, 119, 10509-10524. (Pubitemid 27487990)
42. Ravi, M.; Hopfinger, A.J.; Hormann, R.E.; Dinan, L. 4D-QSAR analysis of a set of ecdysteroids and a comparison to CoMFA modeling. J. Chem. Inf. Comput. Sci., 2001, 41, 1587-1604.
43. Martins, J.P.A.; Barbosa, E.G.; Pasqualoto, K.F.M.; Ferreira, M.M.C. LQTA-QSAR: A New 4D-QSAR Methodology. J. Chem. Inf. Model., 2009, 49, 1428-1436.
44. Datar, P.A.; Coutinho, E.C. A CoMFA study of COX-2 inhibitors with receptor based alignment. J. Mol. Graph. Model., 2004, 23, 239-251. (Pubitemid 39463103)
45. Huang, H.Q.; Pan, X.L.; Tan, N.H.; Zeng, G.Z.; Ji, C.J. 3D-QSAR study of sulfonamide inhibitors of human carbonic anhydrase II. Eur. J. Med. Chem., 2007, 42, 365-372.
46. Ma, X.; Zhou, L.; Zuo, Z.L.; Liu, J.; Yang, M.; Wang, R.W. Molecular docking and 3-D QSAR studies of substituted 2,2-bisaryl-bicycloheptanes as human 5-Lipoxygenase-Activating Protein (FLAP) inhibitors. Qsar. Comb. Sci., 2008, 27, 1083-1091.
47. Palomer, A.; Pascual, J.; Cabre, F.; Garcia, M.L.; Mauleon, D. Derivation of pharmacophore and CoMFA models for leukotriene D-4 receptor antagonists of the quinolinyl(bridged) aryl series. J. Med. Chem., 2000, 43, 392-400. (Pubitemid 30102079)
48. Long, W.; Liu, P.X.; Li, Q.; Xu, Y.; Gao, J. 3D-QSAR studies on a class of IKK-2 inhibitors with GALAHAD used to develop molecular alignment models. Qsar. Comb. Sci., 2008, 27, 1113-1119.
49. Chen, Y.D.; Li, F.F.; Tang, W.Q.; Zhu, C.C.; Jiang, Y.J.; Zou, J.W.; Yu, Q.S.; You, Q.D. 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment. Eur. J. Med. Chem., 2009, 44, 2868-2876.
50. Narkhede, S.S.; Degani, M.S. Pharmacophore refinement and 3D-QSAR studies of histamine H-3 antagonists. Qsar. Comb. Sci., 2007, 26, 744-753. (Pubitemid 46984720)
51. Dove, S.; Buschauer, A. Improved alignment by weighted field fit in CoMFA of histamine H-2 receptor agonists imidazolylpropylguanidines. Quant. Struct-Act. Rel., 1999, 18, 329-341. (Pubitemid 29504988)
52. Tervo, A.J.; Nyronen, T.H.; Ronkko, T.; Poso, A. Comparing the quality and predictiveness between 3D QSAR models obtained from manual and automated alignment. J. Chem. Inf. Comput. Sci., 2004, 44, 807-816.
53. Cramer, R.D. Topomer CoMFA: A design methodology for rapid lead optimization. J. Med. Chem., 2003, 46, 374-388. (Pubitemid 36139790)
54. Chung, J.Y.; Pasha, F.A.; Chung, H.; Yang, B.S.; Lee, C.; Oh, J.S.; Moon, M.W.; Cho, S.J.; Cho, A.E. Topomer-CoMFA study of tricyclic azepine derivatives-EGFR inhibitors. Mol. Cell. Toxicol., 2008, 4, 78-84.
55. Chuman, H.; Karasawa, M.; Fujita, T. A novel three-dimensional QSAR procedure: Voronoi field analysis. Quant. Struct-Act. Rel., 1998, 17, 313-326. (Pubitemid 28401254)
56. Timofei, S.; Kurunczi, L.; Schmidt, W.; Simon, Z. Steric and electrostatic effects in dye-cellulose interactions by the MTD and CoMFA approaches. Sar. Qsar. Environ. Res., 2002, 13, 219-226.
57. Böhm, H.-J.; Klebe, G.; Kubiny, H. Wirkstoffdesign. Spektrum Akademischer: Heidelberg, 1996.
58. Kim, K.H.M., Y.C. Direct prediction of dissociation constants (pKa's) of clonidine-like imidazolines, 2-substituted imidazoles and 1-methyl-2- substituted-imidazoles from 3D structures using a comparative molecular field analysis (CoMFA) approach. J. Med. Chem., 1991, 34, 2056-2060.
59. Klebe, G.A. U. On the prediction of binding properties of drug molecules by comparative molecular field analysis. J. Med. Chem., 1993, 36, 70-80.
60. Puri, S.; Chickos, J.S.; Welsh, W.J. Three-dimensional quantitative structureproperty relationship (3D-QSPR) models for prediction of thermodynamic properties of polychlorinated biphenyls (PCBs): Enthalpy of sublimation. J. Chem. Inf. Comput. Sci., 2002, 42, 109-116. (Pubitemid 35355331)
61. Puri, S.; Chickos, J.S.; Welsh, W.J. Three-dimensional Quantitative Structure-Property Relationship (3D-QSPR) models for prediction of thermodynamic properties of polychlorinated biphenyls (PCBs): Enthalpy of vaporization. J. Chem. Inf. Comput. Sci., 2002, 42, 299-304. (Pubitemid 35355305)
62. Hirons, L.; Holliday, J.D.; Jelfs, S.P.; Willett, P.; Gedeck, P. Use of the Rgroup descriptor for alignment-free QSAR. Qsar. Comb. Sci., 2005, 24, 611-619. (Pubitemid 41074329)
63. Luo, H.B.; Cheng, Y.K. Quantitative structure-retention relationship of nucleic-acid bases revisited. CoMFA on purine RPLC retention. Qsar. Comb. Sci., 2005, 24, 968-975.
64. Jayatilleke, P.R.N.; Nair, A.C.; Zauhar, R.; Welsh, W.J. Computational studies on HIV-1 protease inhibitors: Influence of calculated inhibitorenzyme binding affinities on the statistical quality of 3D-QSAR CoMFA models. J. Med. Chem., 2000, 43, 4446-4451. (Pubitemid 32046869)
65. Mittal, R.R.; Harris, L.; McKinnon, R.A.; Sorich, M.J. Partial Charge Calculation Method Affects CoMFA QSAR Prediction Accuracy. J. Chem. Inf. Model., 2009, 49, 704-709.
66. Tsai, K.C.; Chen, Y.C.; Hsiao, N.W.; Wang, C.L.; Lin, C.L.; Lee, Y.C.; Li, M.; Wang, B. A comparison of different electrostatic potentials on prediction accuracy in CoMFA and CoMSIA studies. Eur. J. Med. Chem., 2010, 45, 1544-1551.
67. Jung, M.; Kim, H. CoMFA of artemisinin derivatives: Effect of location and size of lattice. Bioorg. Med. Chem. Lett., 2001, 11, 2041-2044. (Pubitemid 32709720)
68. Kunick, C.; Lauenroth, K.; Wieking, K.; Xie, X.; Schultz, C.; Gussio, R.; Zaharevitz, D.; Leost, M.; Meijer, L.; Weber, A.; Jorgensen, F.S.; Lemcke, T. Evaluation and comparison of 3D-QSAR CoMSIA models for CDK1, CDK5, and GSK-3 inhibition by paullones. J. Med. Chem., 2004, 47, 22-36. (Pubitemid 38040487)
69. Bucholtz, E.C.; Tropsha, A. The effect of region size on CoMFA analyses. Med. Chem. Res., 1999, 9, 675-685. (Pubitemid 30261833)
70. Carpy, A. Importance of lipophilicity in molecular design - Foreword. Analusis, 1999, 27, 3-6.
71. Vajragupta, O.; Boonchoong, P.; Wongkrajang, Y. Comparative quantitative structure-activity study of radical scavengers. Bioorg. Med. Chem., 2000, 8, 2617-2628.
72. Nakagawa, Y.; Takahashi, K.; Kishikawa, H.; Ogura, T.; Minakuchi, C.; Miyagawa, H. Classical and three-dimensional QSAR for the inhibition of [H-3]ponasterone A binding by diacylhydrazine-type ecdysone agonists to insect Sf-9 cells. Bioorg. Med., 2005, 13, 1333-1340. (Pubitemid 40164616)
73. Pajeva, I.; Wiese, M. Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: A comparative molecular field analysis study. J. Med. Chem.,1998, 41, 1815-1826. (Pubitemid 28248657)
74. Pajeva, I.K.; Wiese, M. Interpretation of CoMFA results - A probe set study using hydrophobic fields. Quant. Struct-Act. Rel., 1999, 18, 369-379. (Pubitemid 29504992)
75. Bursi, R.; Sawa, M.; Hiramatsu, Y.; Kondo, H. A three-dimensional quantitative structure-activity relationship study of heparin-binding epidermal growth factor shedding inhibitors using comparative molecular field analysis. J. Med. Chem., 2002, 45, 781-788. (Pubitemid 34173931)
76. Bursi, R.; Grootenhuis, A.; van der Louw, J.; Verhagen, J.; de Gooyer, M.; Jacobs, P.; Leysen, D. Structure-activity relationship study of human liver microsomes-catalyzed hydrolysis rate of ester prodrugs of MENT by comparative molecular field analysis (CoMFA). Steroids, 2003, 68, 213-220. (Pubitemid 36298784)
77. Gu, C.M.; Hou, T.J.; Xu, X.J. Comparative molecular field analysis of gamma-hydroxy butenolide endothelin antagonists. Chem. J. Chinese U., 2001, 22, 1864-1868.
78. Pan, Y.M.; Ji, M.J.; Ye, X.Q.; Kuang, P.X. 3D-QSAR analyses of novel benzofuranyl and benzothiophenyl biphenyls as PTP1B inhibitors. Chinese J. Org. Chem., 2003, 23, 167-172.
79. Tuppurainen, K. Frontier orbital energies, hydrophobicity and steric factors as physical QSAR descriptors of molecular mutagenicity. A review with a case study: MX compounds. Chemosphere, 1999, 38, 3015-3030. (Pubitemid 29155045)
80. Chen, H.F.; Yao, X.J.; Petitjean, M.; Xia, H.O.; Yao, J.H.; Panaye, A.; Doucet, J.P.; Fan, B.T. Insight into the bioactivity and metabolism of human glucagon receptor antagonists from 3D-QSAR analyses. Qsar. Comb. Sci., 2004, 23, 603-620. (Pubitemid 39531947)
81. Christensen, H.S.; Boye, S.V.; Thinggaard, J.; Sinning, S.; Wiborg, O.; Schiott, B.; Bols, M. QSAR studies and pharmacophore identification for arylsubstituted cycloalkenecarboxylic acid methyl esters with affinity for the human dopamine transporter. Bioorg. Med. Chem., 2007, 15, 5262-5274. (Pubitemid 46880368)
82. Chen, H.F. Computational study of histamine H-3-receptor antagonist with support vector machines and three dimension quantitative structure activity relationship methods. Ana. Chim. Acta., 2008, 624, 203-209.
83. Wolohan, P.; Reichert, D.E. Use of binding energy in comparative molecular field analysis of isoform selective estrogen receptor ligands. J. Mol. Graph. Model., 2004, 23, 23-38. (Pubitemid 39144404)
84. Maitarad, P.; Saparpakorn, P.; Hannongbua, S.; Kamchonwongpaisan, S.; Tarnchompoo, B.; Yuthavong, Y. Particular interaction between pyrimethamine derivatives and quadruple mutant type dihydrofolate reductase of Plasmodium falciparum: CoMFA and quantum chemical calculations studies. J.Enzyme Inhibi. Med. Chem., 2009, 24, 471-479.
85. Kubinyi, H. QSAR : Hansch analysis and related approaches. VCH: Weinheim, 1993.
86. Kubinyi, H. 3D QSAR in Drug Design. Theory, Methods and Applications. Kubinyi, Hugo ed. ESCOM: Leiden, 1993.
87. van de Waterbeemd, H. Chemometric Methods in Molecular Design. VCH: Weinheim, 1995.
88. van de Waterbeemd, H. Advanced Computer-Assisted Techniques in Drug Discovery. VCH: Weinheim, 1995.
89. Pearson, K. On lines and planes of closest fit to systems of points in space. Philos.Mag., 1901, 6, 559-576.
90. Bush, B.L.; Nachbar, R.B. Sample-distance Partial Least Squares: PLS optimized for many variables, with application to CoMFA. J. Comput. Aided Mol. Des., 1993, 7, 587-619.
91. Clark, R.D. Boosted leave-many-out cross-validation: The effect of training and test set diversity on PLS statistics. J. Comput. Aided Mol. Des., 2003, 17, 265-275. (Pubitemid 37062787)
92. Polanski, J.; Gieleciak, R.; Bak, A. Probability issues in molecular design: Predictive and modeling ability in 3D-QSAR schemes. Comb. Chem. High Throughput Screen., 2004, 7, 793-807. (Pubitemid 39561721)
93. Jojart, B.; Marki, A. Receptor-based QSAR studies of non-peptide human oxytocin receptor antagonists. J. Mol. Graph. Model., 2007, 25, 711-720. (Pubitemid 46188548)
94. Maw, H.H.; Hall, L.H. E-state modeling of corticosteroids binding affinity validation of model for small data set. J. Chem. Inf. Comput. Sci., 2001, 41, 1248-1254.
95. Puntambekar, D.S.; Giridhar, R.; Yadav, M.R. Understanding the antitumor activity of novel tricyclicpiperazinyl derivatives as farnesyltransferase inhibitors using CoMFA and CoMSIA. Eur. J. Med. Chem., 2006, 41, 1279-1292. (Pubitemid 44666225)
96. Nair, P.C.; Sobhia, M.E. CoMFA based de novo design of pyridazine analogs as PTP1B inhibitors. J. Mol. Graph. Model., 2007, 26, 117-123. (Pubitemid 46977251)
97. Ramar, S.; Bag, S.; Tawari, N.R.; Degani, M.S. 3-D-QSAR analysis of 2- (oxalylamino) benzoic acid class of protein tyrosine phosphatase 1B inhibitors by CoMFA and Cerius2.GA. Qsar. Combi. Sci., 2007, 26, 608-617. (Pubitemid 46932850)
98. Golbraikh, A.; Tropsha, A. Beware of q2! J. Mol. Graph. Model., 2002, 20, 269-276.
99. Golbraikh, A.; Shen, M.; Xiao, Z.; Xiao, Y.D.; Lee, K.H.; Tropsha, A. Rational selection of training and test sets for the development of validated QSAR models. J. Comput. Aided. Mol. Des., 2003, 17, 241-253. (Pubitemid 37062785)